Form 4: Alkermes Director Christopher I. Wright Reports Stock Transactions

Director Christopher I. Wright reports acquisition and disposal of Alkermes plc ordinary shares and restricted stock units on June 8, 2024.

Summary

• On June 8, 2024, Christopher I. Wright, a director of Alkermes plc, reported transactions involving the company's ordinary shares and restricted stock units.
• Wright acquired 3,301 ordinary shares through the vesting of restricted stock units.
• Wright disposed of 793 ordinary shares to cover tax obligations at a price of $23.91 per share.
• Following these transactions, Wright directly owns 9,777 ordinary shares.
• Wright also directly owns 3,301 derivative securities in the form of restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, as it simply reports facts.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It doesn't necessarily reflect broader industry trends but offers insight into the actions of a key individual within Alkermes.

Comparison to Industry Standards

• Form 4 filings are standard practice for directors and officers of publicly traded companies like Alkermes, similar to filings made by insiders at companies like Biogen, Vertex Pharmaceuticals, and Incyte.
• The reporting requirements and timelines are consistent across the pharmaceutical and biotechnology industries, ensuring transparency in insider trading activities.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly altering the ownership structure.
• The disposal of shares to cover tax obligations has no direct impact on employees, customers, suppliers, or creditors.

Key Dates